Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 171 - 180 of 243
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: Vel's College of Pharmacy
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Phosphodiesterase 3, 5, 9, PDE3A
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Target Identification
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Vaginal Gel, Vaginal Ring
Developer: Ottawa Hospital Research Institute (OHRI)
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Oral
Developer: HRA Pharma, Gynuity Health Projects, PATH
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Oral
Developer: Stanford University
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), FHI 360
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: Vel's College of Pharmacy
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 31 - 40 of 70
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Development Stage: Compound ID/Selection
Alternative Name: Sperm glycolytic enzyme
Target
Hormonal: No
Developer: University of North Carolina at Chapel Hill, NICHD
Development Stage: Target Validation
Alternative Name: GES IUD
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Prototype Development
Alternative Name: Gonadotropin releasing hormone II
Target
User: Female
Hormonal: Yes
Developer: CICRR, San Antonio, CONRAD
Development Stage: Target Identification
Alternative Name: Lactobacilli; LJ-102
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: Hervana Bio
Development Stage: Lead Optimization
Alternative Name: HIFU
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: Vitality Medical Products
Development Stage: Prototype Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Injectable
Developer: Bayer HealthCare
Development Stage: Prototype Development
Alternative Name: LDH-C4, Lactate dehydrogenase C
Target
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Oral
Developer: Northwestern University
Development Stage: Target Identification
Alternative Name: Leukemia inhibitory factor (LIF) and interleukin-11 (IL-11)
Target
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Alternative Name: (3β,13ξ)-Lup-20(29)-en-3-ol; Clerodol; Monogynol B; Fagarasterol; Farganasterol
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Oral, Other
Development Stage: Lead Optimization

Pages

Displaying 21 - 30 of 121
Alternative Name: DVD2
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: FHI 360
Development Stage: Phase I
Alternative Name: DMAU
User: Male
Hormonal: Yes
Duration Type: Short-acting
Developer: BIOQUAL, Inc., NICHD, University of California at Los Angeles
Development Stage: Phase I
Alternative Name: Depot Medroxyprogesterone Acetate (DMPA) + Testosterone
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: ANZAC Research Institute
Development Stage: Phase I
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: National Research Institute for Family Planning in Beijing
Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: International Partnership for Microbicides, USAID
Development Stage: Phase I
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier, Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Viramal Limited
Development Stage: Pre-clinical
Alternative Name: Merck Vaginal Ring MK-8342B
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Phase III
Alternative Name: Casea S
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360
Development Stage: Phase I

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV